Dimitriοs Mavroudis

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

François‐Clément Bidard, Dieter Peeters, Tanja Fehm et al. · The Lancet Oncology · 2014 · 838 citations

Medicine, Cancer Biology, Oncology +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

Jeffrey J. Molldrem, Said Dermime, Kenneth C. Parker et al. · Blood · 1996 · 330 citations · Full text

Life Sciences, Immunology, Oncology +17

Antithymocyte globulin for patients with myelodysplastic syndrome

Jeffrey J. Molldrem, Mary Caples, Dimitriοs Mavroudis et al. · British Journal of Haematology · 1997 · 276 citations

Medicine, Hematology, Pharmacotherapy +17

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies

Dimitriοs Mavroudis, E.J. Read, Michele Cottler‐Fox et al. · Blood · 1996 · 243 citations · Full text

Medicine, Cell Biology, Hematology +17